• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Athersys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    1/8/24 7:31:19 AM ET
    $ATHX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATHX alert in real time by email
    athx20240107_8k.htm
    false 0001368148 0001368148 2024-01-05 2024-01-05
     


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
     

     
    FORM 8-K
     

     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
     
    Date of report (Date of earliest event reported): January 5, 2024
     
    ATHERSYS, INC.
    ATHERSYS, INC / NEW
    (Exact Name of Registrant as Specified in Charter) 
     

     
    Delaware
    001-33876
    20-4864095
    (State or Other Jurisdiction
    of Incorporation)
    (Commission
    File Number)
    (I.R.S. Employer
    Identification No.)
     
     
    3201 Carnegie Avenue,  Cleveland,   Ohio
     
    44115-2634
    (Address of principal executive offices)
     
    (Zip Code)
     
    Registrant’s telephone number, including area code: (216) 431-9900
     
     
    (Former Name or Former Address, if Changed Since Last Report)
     

     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
    Trading Symbol
    Name of each exchange on which registered
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company  ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
     


     
     

     
     
    Item 1.01         Entry into a Material Definitive Agreement
     
    The information set forth under Item 1.03 of this Current Report on Form 8-K (this “Current Report”) regarding the Asset Purchase Agreement (as defined below) and the information set forth under Item 2.03 of this Current Report regarding the DIP Financing Agreement (as defined below) is incorporated by reference into this Item 1.01.
     
    Item 1.03         Bankruptcy or Receivership
     
    Bankruptcy Filing
     
    On January 5, 2024 (the “Petition Date”), Athersys, Inc. (the “Company”) and its direct and indirect subsidiaries, ABT Holding Company, Advanced Biotherapeutics, Inc., ReGenesys, LLC, and ReGenesys BVBA (collectively with the Company, the “Debtors”), filed voluntary petitions (the “Bankruptcy Petitions”) for relief under Chapter 11 of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Northern District of Ohio (such court, the “Court”; and such cases, the “Cases”). The Debtors have filed a motion with the Court seeking joint administration of the Cases, with the Company as the lead debtor under the caption “In re Athersys, Inc., et. al.,” in Case No. 24-10043. The Debtors will continue to manage their assets as “debtors-in-possession” under the jurisdiction of the Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Court.
     
    To ensure a smooth transition into chapter 11, as well as the efficient administration of the Cases, the Debtors have filed various “first day” motions with the Bankruptcy Court requesting customary relief, including authority to obtain postpetition financing to fund the Cases. The Debtors also have filed a motion with the Court seeking approval of certain sale, bid, and auction procedures by which they will seek to sell substantially all of their assets to the Stalking Horse Bidder (defined below), subject to any higher and better bids at auction. 
     
    There has been no order confirming a plan of reorganization, arrangement, or liquidation of the Debtors’ assets in the Cases. The Company cannot be certain that holders of the Company’s common stock will receive any payment or other distribution on account of their shares in the Cases.
     
    Purchase Agreement
     
    On January 5, 2024, prior to the filing of the Bankruptcy Petitions, the Debtors, entered into a “stalking horse” Asset Purchase Agreement (the “Asset Purchase Agreement”) with HEALIOS K.K. (the “Stalking Horse Bidder” or the “DIP Lender”), pursuant to which, among other things, the Debtors will sell to the Stalking Horse Bidder substantially all of their assets, including but not limited to their contracts, personal property, inventory, intellectual property, intangible property, accounts receivable, permits and approvals, studies, documents, and claims (collectively, other than excluded assets, the “Purchased Assets”). The Asset Purchase Agreement provides that the aggregate consideration to be paid by the Stalking Horse Bidder for the sale of all of the Purchased Assets and the obligations of Sellers as set forth in the Asset Purchase Agreement shall be an amount equal to the sum of $2,000,000 (the “Purchase Price”), in the form of a credit bid as provided for pursuant to the DIP Financing Agreement (defined below), plus the payment of any applicable cure costs for contracts approved for assumption and assignment by the Court at the closing of the transaction (the “Closing”).
     
    Sale, Bidding, and Auction Procedures
     
    Contemporaneously with the filing of the Bankruptcy Petitions, the Debtors filed a motion with the Court to seek approval of proposed bidding procedures (the “Bidding Procedures”) for the sale of the Purchased Assets. Pursuant to the Bidding Procedures, the Debtors will, among other things, (i) provide notice of the sale to all known potential purchasers, (ii) solicit qualified bids, and, if necessary, (iii) conduct an auction to determine the highest and best offer for the Purchased Assets. The Company will manage the bidding process and evaluate the bids in consultation with its advisors and as overseen by the Court.
     
    The Asset Purchase Agreement contains customary representations and warranties of the parties and is subject to a number of conditions to Closing, including, among others, (i) the truth and correctness of representations and warranties of the parties, subject to various standards of accuracy, (ii) material compliance with the obligations of the parties set forth in the Asset Purchase Agreement, (iii) there being in effect no laws or orders restraining in any material respect, preventing or prohibiting the Closing, and (iv) a sale order in the Cases having become a final order of the Court.
     
    The Asset Purchase Agreement is subject to certain customary termination events, including but not limited to, if a court or governmental authority takes action to prohibit entry into the DIP Facility or the sale of the Purchased Assets; if the Debtors fail to meet any of the bankruptcy-related deadlines set forth in the Asset Purchase Agreement; if the Debtors agree to consummate a sale of the Purchased Assets to a bidder other than the Stalking Horse Bidder; if the Debtors’ Bankruptcy Cases are converted to cases under chapter 7 of the Bankruptcy Code; or if the Debtors materially breach the Asset Purchase Agreement or DIP Financing Agreement and fail to cure such breach within three (3) business days from receipt of notice of such breach.
     
    As consideration for and as a material inducement to the Stalking Horse Bidder conducting its due diligence and entering into the Asset Purchase Agreement, in the event that (i) the Debtors close on a transaction with a party other than the Stalking Horse Bidder involving, among other things, the sale of the Purchased Assets (an “Alternative Transaction”), (ii) the Stalking Horse Bidder terminates the Asset Purchase Agreement following an uncured material breach by the Debtors or (iii) if the Stalking Horse Bidder is restricted from credit bidding its secured debt under the DIP Financing Agreement as part of the Purchase Price, then the Stalking Horse Bidder shall be entitled to receive (A) a break-up fee in the amount of Two Hundred Thousand Dollars ($200,000) and (B) reimbursement of attorneys’, accountants’, investment bankers’ and representatives’ reasonable, documented fees and expenses actually incurred with respect to the Asset Purchase Agreement, its approval by the Court, or the closing thereon, up to a total of Three Hundred Thousand Dollars ($300,000), each of which shall be payable at the time of closing any Alternative Transaction.
     
    The foregoing description of the Asset Purchase Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Asset Purchase Agreement, a copy of which is filed as Exhibit 2.1 to this Current Report and is incorporated herein by reference. The Asset Purchase Agreement has been filed with this Current Report to provide investors and security holders with information regarding the Asset Purchase Agreement’s terms. The foregoing description of the Asset Purchase Agreement is not intended to provide any other factual information about the Stalking Horse Bidder. The representations, warranties and covenants contained in the Asset Purchase Agreement were made only for purposes of the Asset Purchase Agreement and as of the specific dates referenced therein, and may be subject to important limitations agreed upon by the contracting parties. The representations and warranties may have been made for the purposes of allocating contractual risk between the parties to the Asset Purchase Agreement instead of establishing these matters as facts and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors are not third-party beneficiaries under the Asset Purchase Agreement and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company or its subsidiaries. Moreover, information concerning the subject matter of such representations, warranties and covenants may change after the date of the Asset Purchase Agreement containing them, which subsequent information may or may not be fully reflected in the Company’s public disclosures.
     
     

     
    Item 2.03         Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
     
    Debtor-in-Possession Financing
     
    On January 5, 2024, in connection with filing the Bankruptcy Petitions and subject to the approval of the Court, the Debtors entered into a certain Secured Superpriority Debtor-in-Possession Financing Agreement (the “DIP Financing Agreement”) with the DIP Lender. If approved by the Court as proposed, the DIP Financing Agreement would provide term loans in an aggregate amount not to exceed $2,250,000 consisting of (i) a term loan not to exceed $850,000 to be available upon the entry by the Court of an order approving the DIP Financing Agreement on an interim basis, (ii) a term loan not to exceed $650,000 to be available upon the entry by the Court of an order approving the DIP Financing Agreement on a final basis, and (iii) 750,000 to be available on or promptly after February 16, 2024.

    Pursuant to sections 364(c)(2) and 364(d)(1) of the Bankruptcy Code, the DIP Lender will be granted and shall have a valid, binding, continuing, enforceable, fully-perfected first priority senior security interest in and lien upon substantially all of the Debtors’ assets to the extent not subject to a specified carveout or to valid, perfected, non-avoidable and enforceable liens in existence as of the Petition Date or valid liens in existence as of the Petition Date that are perfected subsequent to such date to the extent permitted by section 546(b) of the Bankruptcy Code. Subject to the carveout, the DIP Lender will be granted an allowed superpriority administrative claim (the “DIP Superpriority Claims”) in accordance with section 364(c)(1) of the Bankruptcy Code, having a priority in right of payment over any and all other obligations, liabilities and indebtedness of the Debtors, now in existence or hereafter incurred by the Debtors and over any and all administrative expenses or priority claims of any kind, whether arising in the chapter 11 cases or in any superseding chapter 7 cases concerning the Debtors. The DIP Financing Agreements include customary covenants, representations and warranties of the type required of debtors in possession, including but not limited to an obligation to use the proceeds of the loans in accordance with a Court-approved budget.
     
    The DIP Financing Agreement is subject to approval by the Court, which has not been obtained at this time. The foregoing descriptions of the DIP Financing Agreement do not purport to be complete and are subject to, and  qualified in their entirety by, the full text of the DIP Financing Agreement. The Company intends to file copies of the DIP Financing Agreement as an exhibit to a Current Report on Form 8-K following its approval by the Bankruptcy Court and execution by all relevant parties.
     
    Item 7.01         Regulation FD Disclosure
     
    Additional Information on the Cases
     
    Court filings and information about the Cases can be found (i) through the Public Access to Court Electronic Records (PACER) website at https://ecf.ohnb.uscourts.gov/, (ii) by email to counsel to the Company, Nicholas M. Miller, Esq., at [email protected], or (iii) by phone to counsel to the Company, Nicholas M. Miller, Esq., at 312-259-0473. The documents and other information available via website or elsewhere are not incorporated by reference into, and do not constitute part of, this Current Report.
     
    The information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language contained in such filing.
     
     

     
    Item 9.01         Financial Statements and Exhibits.
     
    (d)    Exhibits.
     
    Exhibit No.
     
    Description
    2.1
      Asset Purchase Agreement.
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
    Cautionary Note Regarding the Company’s Common Stock
     
    The Company cautions that trading in the Company’s securities (including, without limitation, the Company’s common stock) during the pendency of the Cases is highly speculative and poses substantial risks. Trading prices (or quotations for prices) for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders of the Company’s securities in the Cases. The Company expects that holders of shares of the Company’s common stock could experience a significant or complete loss on their investment, depending on the outcome of the Cases. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities.
     
    Cautionary Note Regarding Forward-Looking Statements
     
    This Current Report contains statements that are, or may be deemed, “forward-looking statements.” Forward-looking statements generally use forward-looking words, such as “may,” “will,” “could,” “should,” “would,” “project,” “believe,” “anticipate,” “expect,” “estimate,” “continue,” “potential,” “plan,” “forecast” and other words that convey the uncertainty of future events or outcomes. Forward-looking statements include, but are not limited to, information concerning the following: expectations regarding risks attendant to the Chapter 11 bankruptcy process, including the Company’s ability to obtain court approval from the Court with respect to motions or other requests made to the Court throughout the course of the Chapter 11 process, including with respect to the asset sale and the DIP Financing Agreement; the Company’s plans to sell certain assets pursuant to Chapter 11 of the Bankruptcy Code, the outcome and timing of such sale, and the Company’s ability to satisfy closing and other conditions to such sale; the effects of Chapter 11, including increased legal and other professional costs necessary to execute the Company’s wind down, on the Company’s liquidity and results of operations (including the availability of operating capital during the pendency of Chapter 11); the length of time that the Company will operate under Chapter 11 protection and the continued availability of operating capital during the pendency of Chapter 11; the Company’s ability to continue funding operations through the Chapter 11 bankruptcy process, and the possibility that it may be unable to obtain any additional funding as needed; the Company’s ability to meet its financial obligations during the Chapter 11 process and to maintain contracts that are critical to its operations; the Company’s ability to comply with the restrictions imposed by the terms and conditions of the DIP Financing Agreement and other financing arrangements; objections to the Company’s wind down process, the DIP Financing Agreement, or other pleadings filed that could protract the Chapter 11 process; the effects of Chapter 11 on the interests of various constituents and financial stakeholders; the effect of the Chapter 11 filings and any potential asset sale on the Company’s relationships with vendors, regulatory authorities, employees, and other third parties; risks relating to the removal of the Company’s common stock from trading and quotation on the OTC Markets; possible proceedings that may be brought by third parties in connection with the Chapter 11 process or the potential asset sale and risks associated with third-party motions in Chapter 11; the timing or amount of any distributions, if any, to the Company’s stakeholders; the impact and timing of any cost-savings measures and related local law requirements in various jurisdictions; the impact of litigation and regulatory proceedings; expectations regarding financial performance, strategic and operational plans, and other related matters; and other factors discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” section of the Annual Report on Form 10-K for its 2022 fiscal year. These forward-looking statements are not guarantees of the Company’s future performance and involve risks, uncertainties, estimates, and assumptions that are difficult to predict and may be outside of the Company’s control. Therefore, the actual outcomes and results may differ materially from those expressed in or contemplated by the forward-looking statements. Any forward-looking statement speaks only as of the date of this Current Report. Except as may be required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and investors are cautioned not to rely upon them unduly.
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    Date: January 8, 2024
     
    ATHERSYS, INC.
         
     
    By:
    /s/ Kasey Rosado
       
    Kasey Rosado
    Interim Chief Financial Officer
     
     
    Get the next $ATHX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATHX

    DatePrice TargetRatingAnalyst
    11/19/2021$1.25Buy → Neutral
    B of A Securities
    11/19/2021Buy → Neutral
    BofA Securities
    More analyst ratings

    $ATHX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hansen Maia covered exercise/tax liability with 67 shares, decreasing direct ownership by 0.10% to 70,010 units (SEC Form 4)

      4 - ATHERSYS, INC / NEW (0001368148) (Issuer)

      12/21/23 11:37:15 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hansen Maia covered exercise/tax liability with 23,149 shares, decreasing direct ownership by 25% to 70,144 units (SEC Form 4)

      4 - ATHERSYS, INC / NEW (0001368148) (Issuer)

      10/6/23 5:34:28 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Camardo Daniel A. covered exercise/tax liability with 19,993 shares, decreasing direct ownership by 7% to 285,341 units (SEC Form 4)

      4 - ATHERSYS, INC / NEW (0001368148) (Issuer)

      10/6/23 5:28:22 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATHX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Athersys downgraded by B of A Securities with a new price target

      B of A Securities downgraded Athersys from Buy to Neutral and set a new price target of $1.25

      11/19/21 8:21:00 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys downgraded by BofA Securities

      BofA Securities downgraded Athersys from Buy to Neutral

      11/19/21 7:12:53 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATHX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Athersys Inc.

      SC 13G - ATHERSYS, INC / NEW (0001368148) (Subject)

      7/8/22 4:57:01 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Athersys Inc. (Amendment)

      SC 13G/A - ATHERSYS, INC / NEW (0001368148) (Subject)

      2/9/22 3:24:54 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Athersys, Inc. (Amendment)

      SC 13D/A - ATHERSYS, INC / NEW (0001368148) (Subject)

      9/21/21 9:14:13 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATHX
    SEC Filings

    See more

    $ATHX
    Financials

    Live finance-specific insights

    See more

    $ATHX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Athersys Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ATHERSYS, INC / NEW (0001368148) (Filer)

      1/8/24 7:31:19 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Athersys Inc.

      25-NSE - ATHERSYS, INC / NEW (0001368148) (Subject)

      12/27/23 9:01:00 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update

      8-K - ATHERSYS, INC / NEW (0001368148) (Filer)

      12/22/23 5:09:11 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys to Host Business Update Conference Call on August 9th

      Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress and discuss timing to conduct an interim analysis with MASTERS-2, a Phase 3 pivotal trial of MultiStem treatment in ischemic stroke. Date

      7/31/23 1:38:00 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys to Host Business Update Conference Call on April 20th

      Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on April 20, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress and discuss upcoming milestones supporting the pivotal Phase 3 ischemic stroke trial, MASTERS-2. Date April 20, 2023 Time

      4/10/23 3:29:00 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys to Host Business Update Conference Call on February 14th

      Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert "Willie" Mays, Executive Vice President Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress, upcoming milestones and vision for the year. Date February 14, 2023 Time 11:00 a.m. (Eastern Time) Live webcast re

      2/2/23 8:30:00 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys Reports Third Quarter 2023 Financial Results and Business Highlights

      Athersys, Inc. (OTC:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and Recent Corporate and Operational Highlights: Announced results of a blinded interim analysis of Phase 3 MASTERS-2 clinical trial studying MultiStem for treatment of ischemic stroke indicating additional patients would need to be added to the trial to achieve statistical significance with a primary endpoint of mRS Shift Analysis at Day 365. Completed warrant exercise inducement generating gross proceeds of $3.

      11/16/23 8:30:00 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives

      Athersys, Inc. (NASDAQ:ATHX), ("Athersys" or the "Company") a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K. ("Healios") under the acute respiratory distress syndrome ("ARDS") global license. On October 11, 2023, Athersys entered into a warrant exercise inducement offer letter (the "Inducement Letter") with a holder of certain existing warrants ("Holder") to receive new warrants

      10/16/23 4:52:00 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios

      The MOU includes $1.5M to $4.5M near term payments plus up to $150M in milestones Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company's ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients is insufficiently powered to achieve the primary endpoint of mRS Shift analysis at Day 365. There were no safety issues identified. Because the s

      10/10/23 8:30:00 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATHX
    Leadership Updates

    Live Leadership Updates

    See more
    • Athersys Appoints Neema Mayhugh, PhD to its Board of Directors

      Healthcare Executive and Strategy Consultant Brings Considerable Innovation, Commercialization and Entrepreneurial Expertise Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Neema Mayhugh, PhD to its Board of Directors. Dr. Mayhugh is an executive with more than 20 years of experience in healthcare consulting, industry, academic and hospital settings. Dr. Mayhugh currently serves as the Founder and Managing Partner of Wave Strategy, a consultancy focused on the rapid commercialization of healthcare innovations. Under her leadership, Wave Strategy has bridged early-stage t

      8/11/23 8:00:00 AM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Murchinson Issues Letter to Fellow Shareholders Regarding the Urgent Need for Boardroom Change at Nano Dimension

      Believes the Stern-Controlled Board's Decision to Challenge Our Special Meeting Demand – Without Any Valid Justification – Reinforces the Need for Objective and Independent Perspectives in the Boardroom Contends the Company is Making Misleading Claims About Murchinson to Distract from Mr. Stern Having Presided Over a More Than 77% Share Price Decline Since Becoming Chairman Puts Forward Proposals to Remove Four Incumbents and Appoint Two Highly Qualified, Independent Director Candidates with Sorely Needed Capital Allocation Acumen and Corporate Governance Expertise Sees a Clear Opportunity to Optimize Nano Dimension's Overcapitalized Balance Sheet, Explore Strategic Options to Maximize V

      2/2/23 5:25:00 PM ET
      $ATHX
      $IMMR
      $NNDM
      $SSYS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Computer peripheral equipment
      Technology
    • Athersys Appoints Joseph Nolan to Its Board of Directors

      Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Joseph "Joe" Nolan to its Board of Directors, effective January 4, 2023. Mr. Nolan is an experienced biotechnology and pharmaceutical executive who currently serves as Chief Executive Officer of Jaguar Gene Therapy, LLC. With this appointment, Athersys has five Directors, four of whom are independent. "Joe is a strong addition to our Board, bringing more than 30 years of experience managing high-value global pipelines, launching multiple successful drugs and optimizing large-scale commercial operations. His understanding of th

      1/5/23 4:33:00 PM ET
      $ATHX
      Biotechnology: Pharmaceutical Preparations
      Health Care